San Francisco, CA, December 15, 2025 (Yahoo Finance) -- OpenAI-backed biotech startup Chai Discovery raised $130 million in a Series B financing round, pushing its valuation to $1.3 billion. The round was led by General Catalyst and Oak HC/FT, with participation from Menlo Ventures, OpenAI, Thrive Capital, SV Angel, Emerson Collective, and others, bringing total funding to more than $225 million. Chai develops AI foundation models for drug discovery, and says its latest pla

Yardley, PA, December 5, 2025 (PR Newswire) -- Jubilant Therapeutics announced the appointment of Daniel J. O’Connor as President and Chief Executive Officer, effective December 1, 2025, as the company advances its clinical-stage oncology and autoimmune pipeline. O’Connor brings more than three decades of leadership experience in biotechnology, most recently guiding Ambrx Biopharma through a period of significant value creation that culminated in its acquisition. His prior

Brisbane, CA, December 09, 2025 (Globe Newswire) -- Vera Therapeutics announced the pricing of an underwritten public offering of just over 6.1 million Class A shares at $42.50 per share, generating approximately $261 million in gross proceeds before fees. The company also granted underwriters a 30-day option to purchase up to an additional 920,716 shares, which could further increase the total raise. Proceeds are expected to support Vera’s late-stage clinical development p

Galway, Ireland, December 17, 2025 (Business Wire) -- AVeta Medical announced the appointment of Karen Noblett, M.D., as Chief Executive Officer, marking a leadership transition as the company advances its VITA AV™ platform for genitourinary syndrome of menopause. Noblett joins from Axonics, where she served as Chief Medical Officer and led clinical strategy, regulatory programs, and physician education supporting the global adoption of sacral neuromodulation technologies.

New York, NY, December 17, 2025 (Reuters) -- Medline shares surged 20.7% in their New York debut after the medical supplies company raised $6.26 billion in an upsized initial public offering, valuing the business at roughly $46 billion and making it the largest U.S. IPO since Rivian’s 2021 listing. Backed by Blackstone, Carlyle and Hellman & Friedman, Medline sold 216 million shares at $29 each, cementing the biggest private-equity-backed IPO on record and the largest globa

Tarrytown, NY and Somerville, MA, December 1, 2025 (Globe Newswire) -- Regeneron Pharmaceuticals and Tessera Therapeutics are collaborating to develop TSRA-196, an in vivo Gene Writing therapy targeting alpha-1 antitrypsin deficiency (AATD), a genetic disease affecting lungs and liver in roughly 200,000 people in the U.S. and Europe. The therapy aims to correct the underlying mutation and restore functional protein through a one-time durable treatment. Tessera will lead ini

Baar, Switzerland and Portsmouth, NH, December 3, 2025 (Business Wire) -- Novocure (NASDAQ: NVCR) named Frank Leonard as its new Chief Executive Officer, effective immediately, following the resignation of Ashley Cordova. Leonard, previously Novocure’s President, has spent over 15 years leading global business operations and helping launch the company’s device-based cancer therapies. William Doyle, Executive Chairman, highlighted Leonard’s pivotal role in shaping Novocure’s

St. Paul, MN, November 20, 2025 (PRNewswire) -- Solventum (NYSE: SOLV) will acquire Acera Surgical, a private bioscience company specializing in fully engineered materials for regenerative wound care, for $725 million in cash plus up to $125 million in milestone-based payments. Acera, founded in 2013, markets Restrata® products in the U.S., used to treat complex, hard-to-heal wounds in acute care settings. Read full article here .

New York, December 3, 2025 (PRNewswire) -- Baird Medical appointed Mark Saxton as CEO of its U.S. subsidiary, bringing over 25 years of medtech leadership including experience at NeuroPace, Smith + Nephew, and Covidien. Saxton will lead U.S. operations, driving the expansion of Baird’s minimally invasive Microwave Ablation (MWA) platform. Read full article here .

Chicago, IL, November 24, 2025 (finance yahoo) -- GE HealthCare (GEHC) announced it will acquire Intelerad, a cloud-based medical imaging software leader, in a $2.3 billion all-cash transaction. The acquisition expands GEHC’s cloud and AI-enabled imaging capabilities across inpatient and outpatient settings, supporting its long-term precision care strategy. The deal brings Intelerad’s outpatient expertise into GEHC’s hospital-focused portfolio, creating a more connected ent

Palo Alto, CA, November 3, 2025 (Business Wire) -- Hippocratic AI raised $126 million in a Series C round, bringing its total funding to $404 million and valuing the company at $3.5 billion. The round was led by Avenir Growth with participation from CapitalG, General Catalyst, Andreessen Horowitz, Kleiner Perkins, Premji Invest, and major health systems including UHS, Cincinnati Children’s, and WellSpan Health. The company plans to use the capital for global expansion, prod

New York, November 12, 2025 (Globe Newswire) -- Ovid Therapeutics unveiled a CEO succession plan in which Meg Alexander will become Chief Executive Officer and join the Board on January 1, 2026, while co-founder Dr. Jeremy Levin shifts to Executive Chairman. The announcement accompanied the company’s third-quarter 2025 financial results and updates on its pipeline progress. Alexander, who has played a key role in shaping the company’s strategy and operations since 2021, wil

New Haven, CT, November 17, 2025 (Reuters) -- Johnson & Johnson will acquire Halda Therapeutics in a $3.05 billion all-cash deal aimed at accelerating Halda’s RIPTAC™ platform for solid tumors. The lead candidate, HLD-0915, recently reported promising Phase 1/2 results in metastatic castration-resistant prostate cancer, showing good tolerability along with reductions in PSA levels and RECIST-based tumor responses. Halda’s broader pipeline includes multiple RIPTAC programs t

Sydney & Boston, November 17, 2025 (Business Wire) -- AdvanCell has appointed biopharma executive Philina Lee, PhD, as its new Chief Executive Officer, effective January 1, 2026. Based in the company’s new U.S. headquarters near Boston/Cambridge, she will spearhead the company’s American expansion while advancing clinical, manufacturing, and partnership efforts for its targeted alpha therapy pipeline. Dr. Lee brings extensive radiopharmaceutical and oncology experience, hav

New York, November 13, 2025 (Business Wire) -- Pfizer completed its purchase of Metsera for $65.60 per share in cash, valuing the company at approximately $7.0 billion, with an additional contingent value right of up to $20.65 per share tied to three clinical and regulatory milestones. The deal adds multiple metabolic assets, including MET-097i, a weekly or monthly GLP-1 RA entering Phase 3, MET-233i, a monthly amylin analog in Phase 1, an oral GLP-1 RA in Phase 1, and addi

Berkeley, CA, November 4, 2025 (Globe Newswire) -- Azalea Therapeutics has launched with $82 million in seed and Series A funding led by Third Rock Ventures to advance its Enveloped Delivery Vehicle (EDV) platform for in vivo cell engineering. Founded by CRISPR pioneer Jennifer Doudna and colleagues, Azalea’s technology enables cell-specific delivery and gene insertion directly inside patients, eliminating the need for ex vivo manufacturing. The company plans to develop in

Rockville, MD, November 4, 2025 (Business Wire) -- BrainScope announced the appointment of Matt Adams as Chief Executive Officer, succeeding Laurie Silver, who becomes President and continues guiding strategy and growth. Adams, a veteran MedTech leader with over $1.3 billion in realized shareholder value, will focus on scaling BrainScope’s AI-driven diagnostics platform for neurological health. The company, known for the first FDA-cleared machine learning device in neurolo

Delaware, November 5, 2025 (finance yahoo) -- Braveheart Bio has emerged from stealth with $185 million in Series A funding to advance BHB-1893, a potential best-in-class treatment for hypertrophic cardiomyopathy licensed from China’s Hengrui Pharma. The company plans to launch global late-stage trials in 2026. Led by former HI-Bio CEO Travis Murdoch and chaired by Biogen’s Chris Viehbacher, Braveheart joins a growing wave of biotech startups licensing late-stage drugs from

Salt Lake City, UT, November 5, 2025 (Globe Newswire) -- Recursion (NASDAQ: RXRX), a leading TechBio company integrating AI, biology, and chemistry, announced a planned leadership transition effective January 1, 2026. Co-founder and current CEO Chris Gibson will assume the role of Chairman of the Board, while Najat Khan, Ph.D., currently Chief R&D and Commercial Officer, will become CEO and President. The move aims to ensure continuity as Recursion advances its platform and

Waltham, MA, October 29, 2025 (Business Wire) -- Thermo Fisher Scientific announced a definitive agreement to acquire Clario Holdings, a global leader in digital clinical endpoint data solutions, for $8.875 billion in cash plus potential earnouts. The acquisition enhances Thermo Fisher’s capabilities in AI-driven clinical data integration, enabling pharma and biotech clients to accelerate innovation through deeper, faster insights. Expected to close mid-2026, the deal will